MARY1

MARY1 is a selective 5-HT2BR antagonist with an IC50 of 380 nM and a Ki of 764 nM [human 5-HT2BR]. It promotes mitochondrial biogenesis (MB) in the kidneys and enhances mitochondrial function by increasing mitochondrial respiration capacity, protein levels, and number in renal proximal tubular cells (RPTC) . MARY1 induces MB in RPTCs through the 5-HT2BR and dual PI3K/AKT and RAS/MEK/ERK signaling pathways. It is useful for studying kidney diseases related to metabolic and mitochondrial dysfunction.